- Approval Id
- 6bf274ef3f32906e
- Drug Approval Emc Name
- Avacopan Vifor 10 mg hard capsules
- Drug Name
- Avacopan Vifor 10 mg hard capsules
- Company Name
- Vifor Fresenius Medical Care Renal Pharma UK Ltd
- Company Address
- Point, 29 Market Street, Maidenhead, SL6 8AA, UK
- Company Telephone
- +44 (0)1276 853 600
- Company Medical Info Direct Line
- +44 (0)1276 853 633
- Company Medical Info Email
- medicalinfo_UK@viforpharma.com
- Atc Code
- L04AJ05
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Vifor Fresenius Medical Care Renal Pharma France
100–101 Terrasse Boieldieu
Tour Franklin La Défense 8
92042 Paris la Défense Cedex
France
- Authorisation Number
- PLGB 50784/0008
- Authorisation Date
- 06/05/2022
- Instruction Authorisation Holder
- Vifor Fresenius Medical Care Renal Pharma France
100–101 Terrasse Boieldieu
Tour Franklin La Défense 8
92042 Paris la Défense Cedex
France
- Instruction Authorisation Number
- PLGB 50784/0008
- Instruction Authorisation Date
- 06/05/2022
- Instruction Composition
- Each hard capsule contains 10 mg of avacopan.
\*\*Excipient with known effect\*\*
Each hard capsule contains 245 mg of macrogolglycerol hydroxystearate.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Hard capsule
Capsules with yellow body and light orange cap with “CCX168” in black ink.
One capsule has a length of 22 mm and a diameter of 8 mm (size 0).
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Avacopan Vifor, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) (see section 4.2).4.2 Posology and method of administration
Treatment should be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA (see section 4.4).
\*\*Posology\*\*
The recommended dose is 30 mg Avacopan Vifor (3 hard capsules of 10 mg each) taken orally twice daily, morning and evening, with food.
Avacopan Vifor should be administered in combination with a rituximab or cyclophosphamide regimen as follows:
• rituximab for 4 weekly intravenous doses or,
• intravenous or oral cyclophosphamide for 13 or 14 weeks, followed by oral azathioprine or mycophenolate mofetil and,
• glucocorticoids as clinically indicated.
For details on doses, concomitant glucocorticoids and data on efficacy and safety for the combinations, please see sections 4.8 and 5.1.
Clinical study data are limited to 52 weeks of exposure followed by 8 weeks of observation.
\*Missed doses\*
If a patient misses a dose, the missed dose is to be taken as soon as possible, unless within three hours of the next scheduled dose. If within three hours, then the missed dose is not to be taken.
Dose management
Treatment must be re-assessed clinically and temporarily stopped if:
• alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is more than 3 times the upper limit of normal (ULN).
Treatment must be temporarily stopped if:
• ALT or AST > 5 × ULN,
• a patient develops leukopenia (white blood cell count < 2 × 109/L) or neutropenia (neutrophils < 1 × 109/L), or lymphopenia (lymphocytes < 0.2 × 109/L),
• a patient has an active, serious infection (i.e. requiring hospitalisation or prolonged hospitalisation).
Treatment may be resumed:
• upon normalisation of values and based on an individual benefit/risk assessment.
If treatment is resumed, hepatic transaminases and total bilirubin are to be monitored closely.
Permanent discontinuation of treatment must be considered if:
• ALT or AST > 8 × ULN,
• ALT or AST > 5 × ULN for more than 2 weeks,
• ALT or AST > 3 × ULN and total bilirubin > 2 × ULN or international normalised ratio (INR) > 1.5,
• ALT or AST > 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%),
• an association between avacopan and hepatic dysfunction has been established.
\*\*\*Special populations\*\*\*
\*Elderly\*
No dose adjustment is required in elderly patients (see section 5.2).
\*Hepatic impairment\*
No dose adjustment is required for patients with mild or moderate hepatic impairment (see section 5.2).
Avacopan has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and it is therefore not recommended for use in these patient populations.
\*Renal impairment\*
No dose adjustment is needed based on renal function (see section 5.2).
Avacopan has not been studied in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis with an estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m2, who are on dialysis, in need of dialysis or plasma exchange.
\*Severe disease manifested as alveolar haemorrhage\*
Avacopan has not been studied in patients with severe disease manifested as alveolar haemorrhage.
\*Paediatric population\*
The safety and efficacy of avacopan in adolescents (12 to 17 years of age) have not yet been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made. The safety and efficacy of avacopan in children below 12 years of age have not yet been established. No data are available.
\*\*Method of administration\*\*
This medicinal product is for oral use.
The hard capsules are to be taken with food and swallowed whole with water and must not be crushed, chewed, or opened.
Grapefruit and grapefruit juice are to be avoided in patients treated with avacopan (see section 4.5).4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Hepatotoxicity\*\*
Serious adverse reactions of elevated hepatic transaminases with elevated total bilirubin have been observed in patients receiving avacopan in combination with cyclophosphamide (followed by azathioprine or mycophenolate) or rituximab, and trimethoprim and sulfamethoxazole. In the post-marketing setting, drug-induced liver injury and vanishing bile duct syndrome (VBDS), including cases with fatal outcome, have been reported (see section 4.8).
Hepatic transaminases and total bilirubin must be obtained prior to initiation of therapy.
Avacopan must be avoided in patients with signs of liver disease, such as elevated AST, ALT, alkaline phosphatase (ALP), or total bilirubin > 3 times ULN.
Patients must be monitored for hepatic transaminases and total bilirubin at least every 4 weeks after start of therapy for the first 6 months of treatment, and as clinically indicated thereafter (see section 4.2).
\*\*Blood and immune system\*\*
White blood cell (WBC) count must be obtained prior to initiation of therapy and patients must be monitored as clinically indicated and as part of the routine follow-up of patient's underlying condition (see section 4.2).
Treatment with avacopan must not be initiated if WBC count is < 3.5 × 109/L, or neutrophil count < 1.5 × 109/L, or lymphocyte count < 0.5 × 109/L.
Patients receiving avacopan must be instructed to report immediately any evidence of infection, unexpected bruising, bleeding, or any other manifestations of bone marrow failure.
\*\*Serious infections\*\*
Serious infections have been reported in patients receiving combination agents for treatment of GPA or MPA, including avacopan in combination with rituximab or cyclophosphamide (see section 4.8).
Patients must be assessed for any serious infections.
Avacopan has not been studied in patients with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infections. Before and during treatment, patients must notify their physician if they have been diagnosed with tuberculosis, hepatitis B, hepatitis C, or HIV infection.
Be cautious when treating patients with a history of tuberculosis, hepatitis B, hepatitis C, or HIV infection.
Avacopan does not decrease the formation of the membrane attack complex (C5b‑9) or terminal complement complex (TCC). No cases of \*Neisseria meningitidis\* have been identified in the avacopan clinical programme. Monitor patients treated for ANCA-associated vasculitis according to standard practice for clinical signs and symptoms of \*Neisseria\* infections.
\*\*\*Pneumocystis jirovecii\*\*\* \*\*pneumonia prophylaxis\*\*
\*Pneumocystis jirovecii\* pneumonia prophylaxis is recommended for adult patients with GPA or MPA during avacopan treatment, as appropriate according to local clinical practice guidelines.
\*\*Immunisation\*\*
The safety of immunisation with live vaccines, following avacopan therapy has not been studied.
Administer vaccinations preferably prior to initiation of treatment with avacopan or during quiescent phase of the disease.
\*\*Angioedema\*\*
Angioedema has been reported in patients receiving avacopan (see section 4.8).
Patients must notify their physician if they develop any symptoms such as swelling of the face, lips, or tongue, throat tightness, or difficulty breathing.
Avacopan must be withheld in cases of angioedema.
\*\*Interaction with strong CYP3A4 inducers\*\*
The use of strong CYP3A4 enzyme inducers (e.g., carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampicin, and St. John's Wort) with avacopan is to be avoided (see section 4.5).
Patients anticipated to require long-term administration of these medicinal products are not to be treated with avacopan.
If short-term co-administration cannot be avoided in a patient already using avacopan, the patient must be closely monitored in case of any reoccurrence of disease activity.
\*\*Cardiac disorders\*\*
Patients with GPA or MPA are at risk of cardiac disorders such as myocardial infarction, cardiac failure, and cardiac vasculitis.
Serious adverse events (SAEs) of cardiac disorder have been reported in patients treated with avacopan. A treatment regimen based on the combination with cyclophosphamide followed by azathioprine may carry an increased risk for cardiac disorders as compared to a regimen based on the combination with rituximab.
\*\*Malignancy\*\*
Immunomodulatory medicinal products may increase the risk for malignancies. The clinical data are currently limited (see section 5.1).
\*\*Macrogolglycerol hydroxystearate content\*\*
This medicinal product contains macrogolglycerol hydroxystearate, which may cause stomach upset and diarrhoea.4.5 Interaction with other medicinal products and other forms of interaction
Avacopan is a substrate of CYP3A4. Co-administration of inducers or inhibitors of this enzyme may affect the pharmacokinetics of avacopan.
\*\*Effect of strong CYP3A4 inducers on avacopan\*\*
Co-administration of avacopan with rifampicin, a strong CYP3A4 enzyme inducer, resulted in a decrease in area-under-the-concentration time curve (AUC) and maximum plasma concentration (Cmax) of avacopan by approximately 93% and 79%, respectively. Since this interaction may result in loss of efficacy of avacopan, the use of strong CYP3A4 enzyme inducers (e.g., carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampicin, and St. John's Wort) with avacopan is to be avoided (see section 4.4). Patients anticipated to require long-term administration of these medicinal products are not to be treated with avacopan. If short-term co-administration cannot be avoided in a patient already using avacopan, the patient must be closely monitored for any reoccurrence of disease activity.
\*\*Effect of moderate CYP3A4 inducers on avacopan\*\*
Exercise caution when using moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, and modafinil) prescribed as concomitant medicinal product with avacopan and carefully evaluate the benefit/risk of avacopan.
\*\*Effect of strong CYP3A4 inhibitors on avacopan\*\*
Co-administration of avacopan with itraconazole, a strong CYP3A4 enzyme inhibitor, resulted in an increase in AUC and Cmax of avacopan by approximately 2.2-fold and 1.9-fold, respectively. Therefore, strong CYP3A4 enzyme inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole) should be used with caution in patients who are being treated with avacopan. Patients must be monitored for potential increase of side effects due to the increased exposure of avacopan.
Grapefruit and grapefruit juice can increase the concentration of avacopan; therefore, grapefruit and grapefruit juice are to be avoided in patients treated with avacopan.
\*\*Effect of avacopan on other medicinal products\*\*
Avacopan is a moderate inhibitor of CYP3A4 \*in vivo\* and may increase the plasma exposures of concomitant medicinal products that are CYP3A4 substrates (e.g., alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, sirolimus and tacrolimus). Patients must be managed according to the Summary of Product Characteristics of the concomitant medicinal products. Dose reductions or monitoring of adverse events may be necessary.
In a clinical study, the co-administration of avacopan with simvastatin, a sensitive CYP3A4 substrate, increased the total systemic exposure (AUC) of simvastatin by 3.5-fold and Cmax by 3.2-fold. Please consult the Summary of Product Characteristics for simvastatin for appropriate dose adjustments.
\*\*Effect of macrogolglycerol hydroxystearate on sensitive P-glycoprotein (P-gp) substrates\*\*
A clinically relevant effect of the excipient macrogolglycerol hydroxystearate on sensitive P-gp substrates with relatively low bioavailability (e.g., dabigatran etexilate) cannot be excluded. Exercise caution when using low-bioavailability P-gp substrates in patients who are being treated with avacopan.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential/Pregnancy\*\*
There are no data from the use of avacopan in pregnant women.
Studies in animals have shown reproductive toxicity (see section 5.3).
Avacopan is not recommended during pregnancy and in women of childbearing potential not using contraception.
\*\*Breast-feeding\*\*
Avacopan has not been measured in milk of lactating animals; however, avacopan has been detected in the plasma of nursing animal offspring without apparent offspring effects (see section 5.3).
A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with avacopan, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
\*\*Fertility\*\*
There are no data on the effects of avacopan on human fertility. Animal data did not indicate any impairment of male or female fertility (see section 5.3).4.7 Effects on ability to drive and use machines
Avacopan Vifor has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The most common adverse reactions are nausea (23.5%), headache (20.5%), white blood cell count decreased (18.7%), upper respiratory tract infection (14.5%), diarrhoea (15.1%), vomiting (15.1%), and nasopharyngitis (15.1%).
The most common serious adverse reactions are liver function abnormalities (5.4%) and pneumonia (4.8%).
\*\*Tabulated list of adverse reactions\*\*
The adverse reactions observed in the ANCA-associated vasculitis pivotal phase 3 study and in the post-marketing setting in patients treated with avacopan are listed in Table 1 by system organ class (SOC) and by frequency.
Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
\*\*Table 1: Adverse reactions\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Very Common\*\* \*\*(≥ 1/10)\*\* | \*\*Common\*\* \*\*(≥ 1/100 to < 1/10)\*\* | \*\*Uncommon\*\* \*\*(≥ 1/1,000 to < 1/100)\*\* | \*\*Not known\*\* |
| Infections and infestations | Upper respiratory tract infection, Nasopharyngitis | Pneumonia, Rhinitis, Urinary tract infection, Sinusitis, Bronchitis, Gastroenteritis, Lower respiratory tract infection, Cellulitis, Herpes zoster, Influenza, Oral candidiasis, Oral herpes, Otitis media | | |
| Blood and lymphatic system disorders | | Neutropenia1 | | |
| Nervous system disorders | Headache | | | |
| Gastrointestinal disorders1 | Nausea, Diarrhoea, Vomiting | Abdominal pain upper | | |
| Hepatobiliary disorders | Liver function test increased1,2 | | | Drug-induced liver injury1, Vanishing bile duct syndrome1 |
| Skin and subcutaneous tissue disorders | | | Angioedema1 | |
| Investigations | White blood cell count decreased3 | Blood creatine phosphokinase increased1 | | |
1 See section “Description of selected adverse reactions”.
2 Alanine aminotransferase increased, total blood bilirubin increased, hepatic function abnormal, gamma glutamyl transferase increased, hepatic enzyme increased, transaminases increased.
3 Includes leukopenia.
\*\*Description of selected adverse reactions\*\*
\*Hepatotoxicity\*
In the pivotal phase 3 study in which 330 patients were dosed, 13.3% of patients in the avacopan group and 11.6% of patients in the prednisone group had an adverse reaction of elevated liver function test (LFT).
In the avacopan group, LFT increased was reported in the phase 3 study and included hepatitis (1.2%), hepatitis cholestatic (0.6%) of which one patient reported both hepatitis and hepatitis cholestatic as a diagnosis, hepatocellular injury (0.6%) in one patient diagnosed with asymptomatic hepatitis, cytolysis and anicteric cholestasis without hepatocellular insufficiency.
In the pivotal phase 3 study, adverse events of hepatobiliary disorders were more frequent in patients treated with a regimen based on a combination with cyclophosphamide followed by azathioprine (10.2%) as compared to those treated with a regimen based on a combination with rituximab (3.7%).
Study medicinal product was paused or discontinued permanently due to LFT increased in 5.4% of patients in the avacopan group and 3.0% of patients in the prednisone group. Serious adverse reactions of LFT increased were reported in 5.4% of patients in the avacopan group and 3.7% of patients in the prednisone group. All serious hepatic events resolved with either the withdrawal of avacopan and/or other potentially hepatotoxic medicinal products, including trimethoprim and sulfamethoxazole.
Drug-induced liver injury and vanishing bile duct syndrome (VBDS) have been reported in the post-marketing setting (see section 4.4).
\*Neutropenia\*
In the pivotal phase 3 study, neutropenia was reported in 4 patients (2.4%) in each treatment group.
A single case of agranulocytosis was reported each in the prednisone group and in the avacopan group.
The patient in the avacopan group was noted to have central neutropenia on a bone marrow biopsy which resolved spontaneously without additional treatment.
\*Creatine phosphokinase increased\*
In the pivotal phase 3 study, 6 patients (3.6%) in the avacopan group and 1 patient (0.6%) in the prednisone group had adverse reactions of increased creatine phosphokinase (CPK).
\*Hypersensitivity including angioedema\*
In the pivotal phase 3 study, 2 patients (1.2%) in the avacopan group had an adverse reaction of angioedema. One patient was hospitalised for the event. Avacopan was paused and both events resolved without sequelae. Avacopan was restarted in one patient and angioedema did not reoccur.
\*Gastrointestinal disorders\*
In the pivotal phase 3 study, adverse reactions of gastrointestinal disorders were observed in 74.6% of patients treated with avacopan and a regimen based on a combination with cyclophosphamide followed by azathioprine as compared to those treated with a regimen based on a combination with rituximab (53.3%).
\*\*Special populations\*\*
\*Paediatric population\*
A total of 3 adolescents were studied in the phase 3 study, one in the prednisone group and two in the avacopan group. There are no data in children below 12 years of age (see section 5.1).
\*Elderly patients\*
The safety profile was similar between patients ≥ 65 years of age and adult patients < 65 years of age in the clinical studies.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.4.9 Overdose
Avacopan was studied in healthy subjects at a maximum total daily dose of 200 mg (given as 100 mg twice daily) for 7 days without evidence of dose limiting toxicities. In case of an overdose, it is recommended that the patient is monitored for any signs or symptoms of adverse effects, and appropriate symptomatic treatment and supportive care are provided.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Complement inhibitors, ATC code: L04AJ05
\*\*Mechanism of action\*\*
Avacopan is a selective antagonist of the human complement 5a receptor (C5aR1 or CD88) and competitively inhibits the interaction between C5aR1 and the anaphylatoxin C5a.
The specific and selective blockade of C5aR1 by avacopan reduces the pro-inflammatory effects of C5a, which include neutrophil activation, migration, and adherence to sites of small blood vessel inflammation, vascular endothelial cell retraction and permeability.
Pharmacodynamic effects
Avacopan blocks the C5a-induced upregulation of CD11b (integrin alpha M) on neutrophils taken from humans dosed with avacopan. CD11b facilitates neutrophil adherence to vascular endothelial surfaces, one of the steps in the vasculitis disease process.
Clinical efficacy and safety
A total of 330 patients aged 13 years or older with granulomatosis with polyangiitis (GPA) (54.8%) or microscopic polyangiitis (MPA) (45.2%) were treated in the active-comparator, randomised, double-blind, double-dummy, multicentre, pivotal phase 3 ADVOCATE study for 52 weeks.
The ADVOCATE study design is depicted in Figure 1.
\*\*Figure 1 ADVOCATE study design\*\*
AZA = azathioprine; CYC = cyclophosphamide; IV = intravenous; MMF = mycophenolate mofetil; RTX =rituximab
Patients were randomised in a 1:1 ratio to one of the two groups:
• Avacopan group (N=166): Patients received 30 mg avacopan twice daily for 52 weeks plus prednisone-matching placebo tapering regimen over 20 weeks,
• Comparator group (N=164): Patients received avacopan-matching placebo twice daily for 52 weeks plus prednisone (tapered from 60 mg/day to 0 over 20 weeks).
All patients in both groups received standard immunosuppressive regimens of either:
• Rituximab at the dose of 375 mg/m2 for 4 weekly intravenous doses, or
• Intravenous cyclophosphamide for 13 weeks (15 mg/kg up to 1.2 g every 2 to 3 weeks), and then starting on week 15 oral azathioprine 1 mg/kg daily with titration up to 2 mg/kg daily (Mycophenolate mofetil 2 g daily was allowed in place of azathioprine. If mycophenolate mofetil was not tolerated or not available, enteric coated mycophenolate sodium could be given at a target dose of 1,440 mg/day), or
• Oral cyclophosphamide for 14 weeks (2 mg/kg daily) followed by oral azathioprine or mycophenolate mofetil/sodium starting at week 15 (same dosing regimen as intravenous cyclophosphamide).
For the first rituximab infusion, 100 mg methylprednisolone, or equivalent was given before starting the infusion with rituximab. Glucocorticoid pre-medication for the second, third, and fourth rituximab infusions was allowed.
Dose reductions or adjustments in cyclophosphamide, azathioprine, and mycophenolate were allowed to conform to standard approaches to maximize safety of these medicinal products.
The following study-supplied glucocorticoid tapering schedule was used (Table 2).
\*\*Table 2: Glucocorticoid tapering schedule – Prednisone dose (mg per day)\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Study Day\*\* | \*\*Avacopan\*\* | \*\*Comparator\*\* | |
| | All | ≥ 55 kg | < 55 kg |
| 1 to 7 | 0 | 60 | 45 |
| 8 to 14 | 0 | 45 | 45 |
| 15 to 21 | 0 | 30 | 30 |
| 22 to 42 | 0 | 25 | 25 |
| 43 to 56 | 0 | 20 | 20 |
| 57 to 70 | 0 | 15 | 15 |
| 71 to 98 | 0 | 10 | 10 |
| 99 to 140 | 0 | 5 | 5 |
| ≥ 141 | 0 | 0 | 0 |
Non-study supplied glucocorticoids, unless strictly necessary due to a condition requiring the use of glucocorticoids (such as adrenal insufficiency), had to be avoided as much as possible during the study. However, patients who experienced worsening or a relapse of their ANCA-associated vasculitis during the study could be treated with a limited course of glucocorticoids.
Patients were stratified at time of randomisation to obtain balance across treatment groups based on 3 factors:
| | |
| --- | --- |
| | Newly-diagnosed or relapsed ANCA-associated vasculitis, Proteinase-3 (PR3) positive or myeloperoxidase (MPO) positive ANCA-associated vasculitis, Receiving either intravenous rituximab, intravenous cyclophosphamide, or oral cyclophosphamide. |
The two treatment groups were well balanced regarding baseline demographics and disease characteristics of patients (Table 3).
\*\*Table 3: Selected baseline characteristics in the pivotal phase 3 ADVOCATE study (Intent-to-Treat Population)\*\*
| | | |
| --- | --- | --- |
| \*\*Demographic characteristic\*\* | \*\*Avacopan\*\* \*\*(N = 166)\*\* | \*\*Comparator\*\* \*\*(N = 164)\*\* |
| Age at screening | | |
| Mean (SD), years | 61 (14.6) | 61 (14.5) |
| Range, years | 13-83 | 15-88 |
| ANCA-associated vasculitis status, n (%) | | |
| Newly diagnosed | 115 (69.3) | 114 (69.5) |
| Relapsed | 51 (30.7) | 50 (30.5) |
| ANCA positivity, n (%) | | |
| PR3 | 72 (43.4) | 70 (42.7) |
| MPO | 94 (56.6) | 94 (57.3) |
| Type of ANCA-associated vasculitis, n (%) | | |
| Granulomatosis with polyangiitis (GPA) | 91 (54.8) | 90 (54.9) |
| Microscopic polyangiitis (MPA) | 75 (45.2) | 74 (45.1) |
| BVAS score | | |
| Mean (SD) | 16.3 (5.87) | 16.2 (5.69) |
| eGFR | | |
| Mean (SD), mL/min/1.73 m2 | 50.7 (30.96) | 52.9 (32.67) |
| Prior Glucocorticoid Use (during Screening) | | |
| n (%) | 125 (75.3) | 135 (82.3) |
| Mean (SD), prednisone-equivalent dose (mg) | 907 (1145.9) | 978 (1157.5) |
ANCA = antineutrophil cytoplasmic autoantibody; BVAS = Birmingham Vasculitis Activity Score; MPO = myeloperoxidase; PR3 = proteinase‑3, SD = standard deviation
The aim of the study was to determine if avacopan could provide an effective treatment for patients with ANCA-associated vasculitis, while also allowing for the reduction of glucocorticoids use without compromising safety or efficacy.
The primary objective was to evaluate the efficacy of the above described treatment regimens to induce and sustain remission in patients with ANCA-associated vasculitis based on the following two primary endpoints:
• the proportion of patients in disease remission defined as achieving a Birmingham Vasculitis Activity Score (BVAS) of 0 and not taking glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to week 26,
• the proportion of patients in sustained remission defined as remission at week 26 without relapse to week 52, and BVAS of 0 and not taking glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to week 52.
The two primary endpoints were tested sequentially for non-inferiority and superiority using a gatekeeping procedure to preserve the Type I error rate at 0.05.
Results from this study are showed in Table 4.
\*\*Table 4: Remission at week 26 and sustained remission at week 52 in the pivotal phase 3 ADVOCATE study (Intent-to-Treat Population)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Avacopan\*\* \*\*N=166\*\* \*\*n (%)\*\* | \*\*Comparator\*\* \*\*N=164\*\* \*\*n (%)\*\* | \*\*Estimate of Treatment Difference in %a\*\* |
| \*\*Remission at week 26\*\* | 120 (72.3) | 115 (70.1) | 3.4 |
| 95% CI | 64.8, 78.9 | 62.5, 77.0 | −6.0, 12.8 |
| \*\*Sustained remission at week 52\*\* | 109 (65.7) | 90 (54.9) | 12.5 b |
| 95% CI | 57.9, 72.8 | 46.9, 62.6 | 2.6, 22.3 |
CI = confidence interval
a Two-sided 95% CIs are calculated by adjusting for randomisation stratification factors.
b superiority p value = 0.013 (2-sided)
The efficacy observed was consistent across pertinent subgroups, i.e., those with newly-diagnosed and relapsed disease, PR3 and MPO ANCA positive, GPA and MPA, and men and women. Efficacy results by background treatment are presented in Table 5.
\*\*Table 5: Remission at week 26 and sustained remission at week 52 in the pivotal phase 3 ADVOCATE study by background treatment (Intent-to-Treat Population)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Avacopan\*\* \*\*n/N (%)\*\* | \*\*Comparator\*\* \*\*n/N (%)\*\* | \*\*Difference in %, 95% CIa\*\* |
| \*\*Remission at week 26\*\* | | | |
| Patients receiving intravenous rituximab | 83/107 (77.6) | 81/107 (75.7) | 1.9 (−9.5, 13.2) |
| Patients receiving intravenous or oral cyclophosphamide | 37/59 (62.7) | 34/57 (59.6) | 3.1 (−14.7, 20.8) |
| \*\*Sustained remission at week 52\*\* | | | |
| Patients receiving intravenous rituximab | 76/107 (71.0) | 60/107 (56.1) | 15.0 (2.2, 27.7) |
| Patients receiving intravenous or oral cyclophosphamide | 33/59 (55.9) | 30/57 (52.6) | 3.3 (−14.8, 21.4) |
a Two-sided 95% confidence intervals (CI) are calculated for the difference in proportions (avacopan minus comparator) using the Wald method.
\*Glucocorticoid toxicity\*
In the pivotal phase 3 ADVOCATE study, the mean total cumulative prednisone-equivalent dose from day 1 to end-of-treatment was approximately 2.3‑fold higher in the comparator group versus the avacopan group (3846.9 mg vs 1675.5 mg, respectively).
From baseline to week 26, 86.1 % of patients using avacopan received non-study supplied glucocorticoids. In the comparator group, the majority of glucocorticoids use was due to the protocol-defined prednisone course.
\*\*Figure 2: Total mean daily prednisone-equivalent glucocorticoid dose (in mg) per patient by study week by treatment group in the ADVOCATE study (Intent-to-Treat Population)\*\*
The Glucocorticoid Toxicity Index (GTI) assesses glucocorticoid-related morbidity, including measures of body mass index, glucose tolerance, lipids, steroid myopathy, skin toxicity, neuropsychiatric toxicity, and infection. A higher GTI indicates greater glucocorticoid toxicity. The GTI contains the Cumulative Worsening Score (CWS) that captures cumulative toxicity over the course of time, and the Aggregate Improvement Score (AIS) that captures both improvement and worsening of toxicity over time.
The two GTI scores (CWS and AIS) of the avacopan group versus the comparator group are summarised in Table 6. The GTI measures were secondary endpoints in the study and not controlled for multiplicity.
\*\*Table 6: Glucocorticoid Toxicity Index results in the pivotal phase 3 ADVOCATE study (Intent-to-Treat Population)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Avacopan\*\* \*\*N = 166\*\* | \*\*Comparator\*\* \*\*N = 164\*\* | \*\*Difference between Groups, 95% CI\*\* |
| \*\*Cumulative Worsening Score (CWS)\*\* | | | |
| Week 13 (least squares mean) | 25.7 | 36.6 | −11.0 (−19.7, −2.2) |
| Week 26 (least squares mean) | 39.7 | 56.6 | −16.8 (−25.6, −8.0) |
| \*\*Aggregate Improvement Score (AIS)\*\* | | | |
| Week 13 (least squares mean) | 9.9 | 23.2 | −13.3 (−22.2, −4.4) |
| Week 26 (least squares mean) | 11.2 | 23.4 | −12.1 (−21.1, −3.2) |
\*\*Paediatric population\*\*
A total of 3 adolescents were studied in the pivotal phase 3 ADVOCATE study, two in the avacopan group and one in the comparator group. One adolescent in the avacopan group discontinued treatment due to worsening renal vasculitis. The second adolescent patient who received avacopan completed treatment, achieved both remission at week 26 and sustained remission at week 52.
The adolescent in the comparator group discontinued treatment due to non-adherence to contraception.
The European Medicines Agency has deferred the obligation to submit the results of studies with avacopan in one or more subsets of the paediatric population in treatment of ANCA-associated vasculitis (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
When administered without food, avacopan peak plasma concentration (Cmax) occurs at a median time (tmax) of approximately 2 hours. Avacopan has shown an approximate dose-proportional increase in systemic exposure in the dose range of 10 to 30 mg.
Co-administration of 30 mg in capsule formulation with a high-fat, high-calorie meal increases the plasma exposure (AUC) of avacopan by approximately 72% and delays tmax by approximately 3 hours; however, the Cmax is not affected.
\*\*Distribution\*\*
The reversible plasma protein binding (e.g., to albumin and α1-acid glycoprotein) of avacopan and metabolite M1 is greater than 99.9%. The apparent volume of distribution is high (Vz/F 3,000 – 11,000 L), indicating broad tissue distribution of the active substance.
\*\*Biotransformation\*\*
Avacopan is eliminated mainly through phase I metabolism. Following oral administration of radiolabelled avacopan, the bulk of the active substance-related materials was recovered in faeces in the form of phase I metabolites. One major circulating metabolite (M1), a mono-hydroxylated product of avacopan, was present at ~ 12% of the total active substance-related materials in plasma. This metabolite constitutes 30 to 50% of the parent exposure and has approximately the same activity as avacopan on C5aR1. Cytochrome P450 (CYP) 3A4 is the major enzyme responsible for the clearance of avacopan and for the formation and clearance of metabolite M1.
Clinical interaction of avacopan with the sensitive CYP3A4 substrate simvastatin is described in section 4.5. Avacopan is a weak inhibitor of CYP2C9 as indicated by a modest increase in the AUC of the probe active substance celecoxib (1.15‑fold).
\*In vitro\*, avacopan is not an inhibitor of other CYP enzymes and is not an inducer of CYP enzymes.
Avacopan showed negligible to weak inhibition of common transporters \*in vitro\*. Therefore, clinically relevant interactions are unlikely when avacopan is co-administered with substances that are substrates or inhibitors of these transporters.
\*\*Elimination\*\*
Based on population pharmacokinetic analysis, the total apparent body clearance (CL/F) of avacopan is 16.3 L/h (95% CI: 13.1 – 21.1 L/h). The median terminal elimination half-life is 510 hours (21 days) based on population pharmacokinetic analysis. When avacopan is stopped after steady state has been reached, the residual plasma concentration of avacopan is projected to decrease to ~ 20%, < 10%, and < 5% of the steady state maximum concentration approximately 4 weeks, 7 weeks, and 10 weeks, respectively, after the last dose.
Following oral administration of radiolabelled avacopan, about 77% and 10% of the radioactivity was recovered in faeces and urine, respectively, and 7% and < 0.1% of the radioactive dose was recovered as unchanged avacopan in faeces and urine, respectively. These results suggest that the main route of clearance of avacopan is metabolism followed by biliary excretion of the metabolites into faeces, and that direct excretion of avacopan into urine or faeces via bile is negligible.
\*\*Special populations\*\*
\*Elderly\*
Population pharmacokinetic analysis found no significant effect of age (among adults) on the plasma exposure of avacopan; however, there were limited pharmacokinetic data in patients over 75 years of age in clinical studies. No dose adjustment is necessary for elderly patients (see section 4.2).
\*Hepatic impairment\*
The pharmacokinetic properties of avacopan have been examined in 16 patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment. When compared to normal controls, no pharmacologically relevant differences in exposure (mean ratios of Cmax and AUC ≤ 1.3) of avacopan or its major metabolite M1 was observed; therefore, no dose adjustment is necessary (see section 4.2).
Avacopan has not been studied in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.2).
\*Renal impairment\*
Based on population pharmacokinetic analysis, the plasma exposure of avacopan is similar between patients with renal impairment and healthy subjects. Therefore, no dose adjustment is necessary based on renal function (see section 4.2).
Avacopan has not been studied in patients with ANCA-associated vasculitis with an eGFR below 15 mL/min/1.73 m2, who are on dialysis, in need of dialysis or plasma exchange.5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenicity.
\*\*Fertility and early embryonic development\*\*
Avacopan produced no effects on male or female reproductive performance (fertility) or early development in hamsters at oral doses equivalent up to 6.8‑fold the clinical AUC.
Embryo-foetal development
Avacopan was not teratogenic when dosed orally to hamsters and rabbits. In hamsters, an increased incidence of skeletal variations (short thoracolumbar supernumerary rib) was observed at exposure equivalent to 5.3‑fold the clinical AUC. In rabbits, avacopan caused maternal toxicity (adverse clinical signs and abortions), but no foetal toxicity at 0.6‑fold the clinical AUC.
Pre- and post-natal development
Avacopan did not result in adverse effects in female offspring when administered in hamsters at exposures up to 6.3‑fold the clinical AUC during gestation and through lactation until weaning. In males, there was a slight delay in preputial separation at 3.7-fold the clinical AUC. This isolated finding was considered to be of low toxicological significance and was not associated with any impairment of reproductive performance.
Analysis of avacopan plasma levels in the lactating dams and the plasma levels in nursing offspring showed the presence of avacopan, suggesting that avacopan is likely secreted into the milk of lactating hamsters.
Carcinogenicity
The carcinogenic potential of avacopan was evaluated in a 2‑year study in both rats and hamsters.
In male rats, a slightly increased incidence of C‑cell thyroid adenoma was noted in avacopan-treated rats; this increase was not statistically significant, and the incidence was within the historical control range. Avacopan was not carcinogenic in hamsters, the pharmacologically relevant species.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Capsule content\*\*
Macrogolglycerol hydroxystearate
Macrogol (4000)
\*\*Capsule shell\*\*
Gelatin
Red iron oxide (E172)
Yellow iron oxide (E172)
Titanium dioxide (E171)
Polysorbate 80
\*\*Imprinting ink\*\*
Black iron oxide (E172)
Shellac
Potassium hydroxide6.2 Incompatibilities
Not applicable.6.3 Shelf life
4 years6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions.
Store in the original bottle in order to protect from light.6.5 Nature and contents of container
High density polyethylene (HDPE) bottle with child-resistant closure and induction seal.
Pack sizes of 30 or 180 hard capsules.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
Each hard capsule contains 10 mg of avacopan.
\*\*Excipient with known effect\*\*
Each hard capsule contains 245 mg of macrogolglycerol hydroxystearate.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Hard capsule
Capsules with yellow body and light orange cap with “CCX168” in black ink.
One capsule has a length of 22 mm and a diameter of 8 mm (size 0).
## Clinical Particulars
4.1 Therapeutic indications
Avacopan Vifor, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) (see section 4.2).4.2 Posology and method of administration
Treatment should be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA (see section 4.4).
\*\*Posology\*\*
The recommended dose is 30 mg Avacopan Vifor (3 hard capsules of 10 mg each) taken orally twice daily, morning and evening, with food.
Avacopan Vifor should be administered in combination with a rituximab or cyclophosphamide regimen as follows:
• rituximab for 4 weekly intravenous doses or,
• intravenous or oral cyclophosphamide for 13 or 14 weeks, followed by oral azathioprine or mycophenolate mofetil and,
• glucocorticoids as clinically indicated.
For details on doses, concomitant glucocorticoids and data on efficacy and safety for the combinations, please see sections 4.8 and 5.1.
Clinical study data are limited to 52 weeks of exposure followed by 8 weeks of observation.
\*Missed doses\*
If a patient misses a dose, the missed dose is to be taken as soon as possible, unless within three hours of the next scheduled dose. If within three hours, then the missed dose is not to be taken.
Dose management
Treatment must be re-assessed clinically and temporarily stopped if:
• alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is more than 3 times the upper limit of normal (ULN).
Treatment must be temporarily stopped if:
• ALT or AST > 5 × ULN,
• a patient develops leukopenia (white blood cell count < 2 × 109/L) or neutropenia (neutrophils < 1 × 109/L), or lymphopenia (lymphocytes < 0.2 × 109/L),
• a patient has an active, serious infection (i.e. requiring hospitalisation or prolonged hospitalisation).
Treatment may be resumed:
• upon normalisation of values and based on an individual benefit/risk assessment.
If treatment is resumed, hepatic transaminases and total bilirubin are to be monitored closely.
Permanent discontinuation of treatment must be considered if:
• ALT or AST > 8 × ULN,
• ALT or AST > 5 × ULN for more than 2 weeks,
• ALT or AST > 3 × ULN and total bilirubin > 2 × ULN or international normalised ratio (INR) > 1.5,
• ALT or AST > 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%),
• an association between avacopan and hepatic dysfunction has been established.
\*\*\*Special populations\*\*\*
\*Elderly\*
No dose adjustment is required in elderly patients (see section 5.2).
\*Hepatic impairment\*
No dose adjustment is required for patients with mild or moderate hepatic impairment (see section 5.2).
Avacopan has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and it is therefore not recommended for use in these patient populations.
\*Renal impairment\*
No dose adjustment is needed based on renal function (see section 5.2).
Avacopan has not been studied in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis with an estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m2, who are on dialysis, in need of dialysis or plasma exchange.
\*Severe disease manifested as alveolar haemorrhage\*
Avacopan has not been studied in patients with severe disease manifested as alveolar haemorrhage.
\*Paediatric population\*
The safety and efficacy of avacopan in adolescents (12 to 17 years of age) have not yet been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made. The safety and efficacy of avacopan in children below 12 years of age have not yet been established. No data are available.
\*\*Method of administration\*\*
This medicinal product is for oral use.
The hard capsules are to be taken with food and swallowed whole with water and must not be crushed, chewed, or opened.
Grapefruit and grapefruit juice are to be avoided in patients treated with avacopan (see section 4.5).4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Hepatotoxicity\*\*
Serious adverse reactions of elevated hepatic transaminases with elevated total bilirubin have been observed in patients receiving avacopan in combination with cyclophosphamide (followed by azathioprine or mycophenolate) or rituximab, and trimethoprim and sulfamethoxazole. In the post-marketing setting, drug-induced liver injury and vanishing bile duct syndrome (VBDS), including cases with fatal outcome, have been reported (see section 4.8).
Hepatic transaminases and total bilirubin must be obtained prior to initiation of therapy.
Avacopan must be avoided in patients with signs of liver disease, such as elevated AST, ALT, alkaline phosphatase (ALP), or total bilirubin > 3 times ULN.
Patients must be monitored for hepatic transaminases and total bilirubin at least every 4 weeks after start of therapy for the first 6 months of treatment, and as clinically indicated thereafter (see section 4.2).
\*\*Blood and immune system\*\*
White blood cell (WBC) count must be obtained prior to initiation of therapy and patients must be monitored as clinically indicated and as part of the routine follow-up of patient's underlying condition (see section 4.2).
Treatment with avacopan must not be initiated if WBC count is < 3.5 × 109/L, or neutrophil count < 1.5 × 109/L, or lymphocyte count < 0.5 × 109/L.
Patients receiving avacopan must be instructed to report immediately any evidence of infection, unexpected bruising, bleeding, or any other manifestations of bone marrow failure.
\*\*Serious infections\*\*
Serious infections have been reported in patients receiving combination agents for treatment of GPA or MPA, including avacopan in combination with rituximab or cyclophosphamide (see section 4.8).
Patients must be assessed for any serious infections.
Avacopan has not been studied in patients with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infections. Before and during treatment, patients must notify their physician if they have been diagnosed with tuberculosis, hepatitis B, hepatitis C, or HIV infection.
Be cautious when treating patients with a history of tuberculosis, hepatitis B, hepatitis C, or HIV infection.
Avacopan does not decrease the formation of the membrane attack complex (C5b‑9) or terminal complement complex (TCC). No cases of \*Neisseria meningitidis\* have been identified in the avacopan clinical programme. Monitor patients treated for ANCA-associated vasculitis according to standard practice for clinical signs and symptoms of \*Neisseria\* infections.
\*\*\*Pneumocystis jirovecii\*\*\* \*\*pneumonia prophylaxis\*\*
\*Pneumocystis jirovecii\* pneumonia prophylaxis is recommended for adult patients with GPA or MPA during avacopan treatment, as appropriate according to local clinical practice guidelines.
\*\*Immunisation\*\*
The safety of immunisation with live vaccines, following avacopan therapy has not been studied.
Administer vaccinations preferably prior to initiation of treatment with avacopan or during quiescent phase of the disease.
\*\*Angioedema\*\*
Angioedema has been reported in patients receiving avacopan (see section 4.8).
Patients must notify their physician if they develop any symptoms such as swelling of the face, lips, or tongue, throat tightness, or difficulty breathing.
Avacopan must be withheld in cases of angioedema.
\*\*Interaction with strong CYP3A4 inducers\*\*
The use of strong CYP3A4 enzyme inducers (e.g., carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampicin, and St. John's Wort) with avacopan is to be avoided (see section 4.5).
Patients anticipated to require long-term administration of these medicinal products are not to be treated with avacopan.
If short-term co-administration cannot be avoided in a patient already using avacopan, the patient must be closely monitored in case of any reoccurrence of disease activity.
\*\*Cardiac disorders\*\*
Patients with GPA or MPA are at risk of cardiac disorders such as myocardial infarction, cardiac failure, and cardiac vasculitis.
Serious adverse events (SAEs) of cardiac disorder have been reported in patients treated with avacopan. A treatment regimen based on the combination with cyclophosphamide followed by azathioprine may carry an increased risk for cardiac disorders as compared to a regimen based on the combination with rituximab.
\*\*Malignancy\*\*
Immunomodulatory medicinal products may increase the risk for malignancies. The clinical data are currently limited (see section 5.1).
\*\*Macrogolglycerol hydroxystearate content\*\*
This medicinal product contains macrogolglycerol hydroxystearate, which may cause stomach upset and diarrhoea.4.5 Interaction with other medicinal products and other forms of interaction
Avacopan is a substrate of CYP3A4. Co-administration of inducers or inhibitors of this enzyme may affect the pharmacokinetics of avacopan.
\*\*Effect of strong CYP3A4 inducers on avacopan\*\*
Co-administration of avacopan with rifampicin, a strong CYP3A4 enzyme inducer, resulted in a decrease in area-under-the-concentration time curve (AUC) and maximum plasma concentration (Cmax) of avacopan by approximately 93% and 79%, respectively. Since this interaction may result in loss of efficacy of avacopan, the use of strong CYP3A4 enzyme inducers (e.g., carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampicin, and St. John's Wort) with avacopan is to be avoided (see section 4.4). Patients anticipated to require long-term administration of these medicinal products are not to be treated with avacopan. If short-term co-administration cannot be avoided in a patient already using avacopan, the patient must be closely monitored for any reoccurrence of disease activity.
\*\*Effect of moderate CYP3A4 inducers on avacopan\*\*
Exercise caution when using moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, and modafinil) prescribed as concomitant medicinal product with avacopan and carefully evaluate the benefit/risk of avacopan.
\*\*Effect of strong CYP3A4 inhibitors on avacopan\*\*
Co-administration of avacopan with itraconazole, a strong CYP3A4 enzyme inhibitor, resulted in an increase in AUC and Cmax of avacopan by approximately 2.2-fold and 1.9-fold, respectively. Therefore, strong CYP3A4 enzyme inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole) should be used with caution in patients who are being treated with avacopan. Patients must be monitored for potential increase of side effects due to the increased exposure of avacopan.
Grapefruit and grapefruit juice can increase the concentration of avacopan; therefore, grapefruit and grapefruit juice are to be avoided in patients treated with avacopan.
\*\*Effect of avacopan on other medicinal products\*\*
Avacopan is a moderate inhibitor of CYP3A4 \*in vivo\* and may increase the plasma exposures of concomitant medicinal products that are CYP3A4 substrates (e.g., alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, sirolimus and tacrolimus). Patients must be managed according to the Summary of Product Characteristics of the concomitant medicinal products. Dose reductions or monitoring of adverse events may be necessary.
In a clinical study, the co-administration of avacopan with simvastatin, a sensitive CYP3A4 substrate, increased the total systemic exposure (AUC) of simvastatin by 3.5-fold and Cmax by 3.2-fold. Please consult the Summary of Product Characteristics for simvastatin for appropriate dose adjustments.
\*\*Effect of macrogolglycerol hydroxystearate on sensitive P-glycoprotein (P-gp) substrates\*\*
A clinically relevant effect of the excipient macrogolglycerol hydroxystearate on sensitive P-gp substrates with relatively low bioavailability (e.g., dabigatran etexilate) cannot be excluded. Exercise caution when using low-bioavailability P-gp substrates in patients who are being treated with avacopan.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential/Pregnancy\*\*
There are no data from the use of avacopan in pregnant women.
Studies in animals have shown reproductive toxicity (see section 5.3).
Avacopan is not recommended during pregnancy and in women of childbearing potential not using contraception.
\*\*Breast-feeding\*\*
Avacopan has not been measured in milk of lactating animals; however, avacopan has been detected in the plasma of nursing animal offspring without apparent offspring effects (see section 5.3).
A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with avacopan, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
\*\*Fertility\*\*
There are no data on the effects of avacopan on human fertility. Animal data did not indicate any impairment of male or female fertility (see section 5.3).4.7 Effects on ability to drive and use machines
Avacopan Vifor has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The most common adverse reactions are nausea (23.5%), headache (20.5%), white blood cell count decreased (18.7%), upper respiratory tract infection (14.5%), diarrhoea (15.1%), vomiting (15.1%), and nasopharyngitis (15.1%).
The most common serious adverse reactions are liver function abnormalities (5.4%) and pneumonia (4.8%).
\*\*Tabulated list of adverse reactions\*\*
The adverse reactions observed in the ANCA-associated vasculitis pivotal phase 3 study and in the post-marketing setting in patients treated with avacopan are listed in Table 1 by system organ class (SOC) and by frequency.
Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
\*\*Table 1: Adverse reactions\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Very Common\*\* \*\*(≥ 1/10)\*\* | \*\*Common\*\* \*\*(≥ 1/100 to < 1/10)\*\* | \*\*Uncommon\*\* \*\*(≥ 1/1,000 to < 1/100)\*\* | \*\*Not known\*\* |
| Infections and infestations | Upper respiratory tract infection, Nasopharyngitis | Pneumonia, Rhinitis, Urinary tract infection, Sinusitis, Bronchitis, Gastroenteritis, Lower respiratory tract infection, Cellulitis, Herpes zoster, Influenza, Oral candidiasis, Oral herpes, Otitis media | | |
| Blood and lymphatic system disorders | | Neutropenia1 | | |
| Nervous system disorders | Headache | | | |
| Gastrointestinal disorders1 | Nausea, Diarrhoea, Vomiting | Abdominal pain upper | | |
| Hepatobiliary disorders | Liver function test increased1,2 | | | Drug-induced liver injury1, Vanishing bile duct syndrome1 |
| Skin and subcutaneous tissue disorders | | | Angioedema1 | |
| Investigations | White blood cell count decreased3 | Blood creatine phosphokinase increased1 | | |
1 See section “Description of selected adverse reactions”.
2 Alanine aminotransferase increased, total blood bilirubin increased, hepatic function abnormal, gamma glutamyl transferase increased, hepatic enzyme increased, transaminases increased.
3 Includes leukopenia.
\*\*Description of selected adverse reactions\*\*
\*Hepatotoxicity\*
In the pivotal phase 3 study in which 330 patients were dosed, 13.3% of patients in the avacopan group and 11.6% of patients in the prednisone group had an adverse reaction of elevated liver function test (LFT).
In the avacopan group, LFT increased was reported in the phase 3 study and included hepatitis (1.2%), hepatitis cholestatic (0.6%) of which one patient reported both hepatitis and hepatitis cholestatic as a diagnosis, hepatocellular injury (0.6%) in one patient diagnosed with asymptomatic hepatitis, cytolysis and anicteric cholestasis without hepatocellular insufficiency.
In the pivotal phase 3 study, adverse events of hepatobiliary disorders were more frequent in patients treated with a regimen based on a combination with cyclophosphamide followed by azathioprine (10.2%) as compared to those treated with a regimen based on a combination with rituximab (3.7%).
Study medicinal product was paused or discontinued permanently due to LFT increased in 5.4% of patients in the avacopan group and 3.0% of patients in the prednisone group. Serious adverse reactions of LFT increased were reported in 5.4% of patients in the avacopan group and 3.7% of patients in the prednisone group. All serious hepatic events resolved with either the withdrawal of avacopan and/or other potentially hepatotoxic medicinal products, including trimethoprim and sulfamethoxazole.
Drug-induced liver injury and vanishing bile duct syndrome (VBDS) have been reported in the post-marketing setting (see section 4.4).
\*Neutropenia\*
In the pivotal phase 3 study, neutropenia was reported in 4 patients (2.4%) in each treatment group.
A single case of agranulocytosis was reported each in the prednisone group and in the avacopan group.
The patient in the avacopan group was noted to have central neutropenia on a bone marrow biopsy which resolved spontaneously without additional treatment.
\*Creatine phosphokinase increased\*
In the pivotal phase 3 study, 6 patients (3.6%) in the avacopan group and 1 patient (0.6%) in the prednisone group had adverse reactions of increased creatine phosphokinase (CPK).
\*Hypersensitivity including angioedema\*
In the pivotal phase 3 study, 2 patients (1.2%) in the avacopan group had an adverse reaction of angioedema. One patient was hospitalised for the event. Avacopan was paused and both events resolved without sequelae. Avacopan was restarted in one patient and angioedema did not reoccur.
\*Gastrointestinal disorders\*
In the pivotal phase 3 study, adverse reactions of gastrointestinal disorders were observed in 74.6% of patients treated with avacopan and a regimen based on a combination with cyclophosphamide followed by azathioprine as compared to those treated with a regimen based on a combination with rituximab (53.3%).
\*\*Special populations\*\*
\*Paediatric population\*
A total of 3 adolescents were studied in the phase 3 study, one in the prednisone group and two in the avacopan group. There are no data in children below 12 years of age (see section 5.1).
\*Elderly patients\*
The safety profile was similar between patients ≥ 65 years of age and adult patients < 65 years of age in the clinical studies.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.4.9 Overdose
Avacopan was studied in healthy subjects at a maximum total daily dose of 200 mg (given as 100 mg twice daily) for 7 days without evidence of dose limiting toxicities. In case of an overdose, it is recommended that the patient is monitored for any signs or symptoms of adverse effects, and appropriate symptomatic treatment and supportive care are provided.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Complement inhibitors, ATC code: L04AJ05
\*\*Mechanism of action\*\*
Avacopan is a selective antagonist of the human complement 5a receptor (C5aR1 or CD88) and competitively inhibits the interaction between C5aR1 and the anaphylatoxin C5a.
The specific and selective blockade of C5aR1 by avacopan reduces the pro-inflammatory effects of C5a, which include neutrophil activation, migration, and adherence to sites of small blood vessel inflammation, vascular endothelial cell retraction and permeability.
Pharmacodynamic effects
Avacopan blocks the C5a-induced upregulation of CD11b (integrin alpha M) on neutrophils taken from humans dosed with avacopan. CD11b facilitates neutrophil adherence to vascular endothelial surfaces, one of the steps in the vasculitis disease process.
Clinical efficacy and safety
A total of 330 patients aged 13 years or older with granulomatosis with polyangiitis (GPA) (54.8%) or microscopic polyangiitis (MPA) (45.2%) were treated in the active-comparator, randomised, double-blind, double-dummy, multicentre, pivotal phase 3 ADVOCATE study for 52 weeks.
The ADVOCATE study design is depicted in Figure 1.
\*\*Figure 1 ADVOCATE study design\*\*
AZA = azathioprine; CYC = cyclophosphamide; IV = intravenous; MMF = mycophenolate mofetil; RTX =rituximab
Patients were randomised in a 1:1 ratio to one of the two groups:
• Avacopan group (N=166): Patients received 30 mg avacopan twice daily for 52 weeks plus prednisone-matching placebo tapering regimen over 20 weeks,
• Comparator group (N=164): Patients received avacopan-matching placebo twice daily for 52 weeks plus prednisone (tapered from 60 mg/day to 0 over 20 weeks).
All patients in both groups received standard immunosuppressive regimens of either:
• Rituximab at the dose of 375 mg/m2 for 4 weekly intravenous doses, or
• Intravenous cyclophosphamide for 13 weeks (15 mg/kg up to 1.2 g every 2 to 3 weeks), and then starting on week 15 oral azathioprine 1 mg/kg daily with titration up to 2 mg/kg daily (Mycophenolate mofetil 2 g daily was allowed in place of azathioprine. If mycophenolate mofetil was not tolerated or not available, enteric coated mycophenolate sodium could be given at a target dose of 1,440 mg/day), or
• Oral cyclophosphamide for 14 weeks (2 mg/kg daily) followed by oral azathioprine or mycophenolate mofetil/sodium starting at week 15 (same dosing regimen as intravenous cyclophosphamide).
For the first rituximab infusion, 100 mg methylprednisolone, or equivalent was given before starting the infusion with rituximab. Glucocorticoid pre-medication for the second, third, and fourth rituximab infusions was allowed.
Dose reductions or adjustments in cyclophosphamide, azathioprine, and mycophenolate were allowed to conform to standard approaches to maximize safety of these medicinal products.
The following study-supplied glucocorticoid tapering schedule was used (Table 2).
\*\*Table 2: Glucocorticoid tapering schedule – Prednisone dose (mg per day)\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Study Day\*\* | \*\*Avacopan\*\* | \*\*Comparator\*\* | |
| | All | ≥ 55 kg | < 55 kg |
| 1 to 7 | 0 | 60 | 45 |
| 8 to 14 | 0 | 45 | 45 |
| 15 to 21 | 0 | 30 | 30 |
| 22 to 42 | 0 | 25 | 25 |
| 43 to 56 | 0 | 20 | 20 |
| 57 to 70 | 0 | 15 | 15 |
| 71 to 98 | 0 | 10 | 10 |
| 99 to 140 | 0 | 5 | 5 |
| ≥ 141 | 0 | 0 | 0 |
Non-study supplied glucocorticoids, unless strictly necessary due to a condition requiring the use of glucocorticoids (such as adrenal insufficiency), had to be avoided as much as possible during the study. However, patients who experienced worsening or a relapse of their ANCA-associated vasculitis during the study could be treated with a limited course of glucocorticoids.
Patients were stratified at time of randomisation to obtain balance across treatment groups based on 3 factors:
| | |
| --- | --- |
| | Newly-diagnosed or relapsed ANCA-associated vasculitis, Proteinase-3 (PR3) positive or myeloperoxidase (MPO) positive ANCA-associated vasculitis, Receiving either intravenous rituximab, intravenous cyclophosphamide, or oral cyclophosphamide. |
The two treatment groups were well balanced regarding baseline demographics and disease characteristics of patients (Table 3).
\*\*Table 3: Selected baseline characteristics in the pivotal phase 3 ADVOCATE study (Intent-to-Treat Population)\*\*
| | | |
| --- | --- | --- |
| \*\*Demographic characteristic\*\* | \*\*Avacopan\*\* \*\*(N = 166)\*\* | \*\*Comparator\*\* \*\*(N = 164)\*\* |
| Age at screening | | |
| Mean (SD), years | 61 (14.6) | 61 (14.5) |
| Range, years | 13-83 | 15-88 |
| ANCA-associated vasculitis status, n (%) | | |
| Newly diagnosed | 115 (69.3) | 114 (69.5) |
| Relapsed | 51 (30.7) | 50 (30.5) |
| ANCA positivity, n (%) | | |
| PR3 | 72 (43.4) | 70 (42.7) |
| MPO | 94 (56.6) | 94 (57.3) |
| Type of ANCA-associated vasculitis, n (%) | | |
| Granulomatosis with polyangiitis (GPA) | 91 (54.8) | 90 (54.9) |
| Microscopic polyangiitis (MPA) | 75 (45.2) | 74 (45.1) |
| BVAS score | | |
| Mean (SD) | 16.3 (5.87) | 16.2 (5.69) |
| eGFR | | |
| Mean (SD), mL/min/1.73 m2 | 50.7 (30.96) | 52.9 (32.67) |
| Prior Glucocorticoid Use (during Screening) | | |
| n (%) | 125 (75.3) | 135 (82.3) |
| Mean (SD), prednisone-equivalent dose (mg) | 907 (1145.9) | 978 (1157.5) |
ANCA = antineutrophil cytoplasmic autoantibody; BVAS = Birmingham Vasculitis Activity Score; MPO = myeloperoxidase; PR3 = proteinase‑3, SD = standard deviation
The aim of the study was to determine if avacopan could provide an effective treatment for patients with ANCA-associated vasculitis, while also allowing for the reduction of glucocorticoids use without compromising safety or efficacy.
The primary objective was to evaluate the efficacy of the above described treatment regimens to induce and sustain remission in patients with ANCA-associated vasculitis based on the following two primary endpoints:
• the proportion of patients in disease remission defined as achieving a Birmingham Vasculitis Activity Score (BVAS) of 0 and not taking glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to week 26,
• the proportion of patients in sustained remission defined as remission at week 26 without relapse to week 52, and BVAS of 0 and not taking glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to week 52.
The two primary endpoints were tested sequentially for non-inferiority and superiority using a gatekeeping procedure to preserve the Type I error rate at 0.05.
Results from this study are showed in Table 4.
\*\*Table 4: Remission at week 26 and sustained remission at week 52 in the pivotal phase 3 ADVOCATE study (Intent-to-Treat Population)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Avacopan\*\* \*\*N=166\*\* \*\*n (%)\*\* | \*\*Comparator\*\* \*\*N=164\*\* \*\*n (%)\*\* | \*\*Estimate of Treatment Difference in %a\*\* |
| \*\*Remission at week 26\*\* | 120 (72.3) | 115 (70.1) | 3.4 |
| 95% CI | 64.8, 78.9 | 62.5, 77.0 | −6.0, 12.8 |
| \*\*Sustained remission at week 52\*\* | 109 (65.7) | 90 (54.9) | 12.5 b |
| 95% CI | 57.9, 72.8 | 46.9, 62.6 | 2.6, 22.3 |
CI = confidence interval
a Two-sided 95% CIs are calculated by adjusting for randomisation stratification factors.
b superiority p value = 0.013 (2-sided)
The efficacy observed was consistent across pertinent subgroups, i.e., those with newly-diagnosed and relapsed disease, PR3 and MPO ANCA positive, GPA and MPA, and men and women. Efficacy results by background treatment are presented in Table 5.
\*\*Table 5: Remission at week 26 and sustained remission at week 52 in the pivotal phase 3 ADVOCATE study by background treatment (Intent-to-Treat Population)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Avacopan\*\* \*\*n/N (%)\*\* | \*\*Comparator\*\* \*\*n/N (%)\*\* | \*\*Difference in %, 95% CIa\*\* |
| \*\*Remission at week 26\*\* | | | |
| Patients receiving intravenous rituximab | 83/107 (77.6) | 81/107 (75.7) | 1.9 (−9.5, 13.2) |
| Patients receiving intravenous or oral cyclophosphamide | 37/59 (62.7) | 34/57 (59.6) | 3.1 (−14.7, 20.8) |
| \*\*Sustained remission at week 52\*\* | | | |
| Patients receiving intravenous rituximab | 76/107 (71.0) | 60/107 (56.1) | 15.0 (2.2, 27.7) |
| Patients receiving intravenous or oral cyclophosphamide | 33/59 (55.9) | 30/57 (52.6) | 3.3 (−14.8, 21.4) |
a Two-sided 95% confidence intervals (CI) are calculated for the difference in proportions (avacopan minus comparator) using the Wald method.
\*Glucocorticoid toxicity\*
In the pivotal phase 3 ADVOCATE study, the mean total cumulative prednisone-equivalent dose from day 1 to end-of-treatment was approximately 2.3‑fold higher in the comparator group versus the avacopan group (3846.9 mg vs 1675.5 mg, respectively).
From baseline to week 26, 86.1 % of patients using avacopan received non-study supplied glucocorticoids. In the comparator group, the majority of glucocorticoids use was due to the protocol-defined prednisone course.
\*\*Figure 2: Total mean daily prednisone-equivalent glucocorticoid dose (in mg) per patient by study week by treatment group in the ADVOCATE study (Intent-to-Treat Population)\*\*
The Glucocorticoid Toxicity Index (GTI) assesses glucocorticoid-related morbidity, including measures of body mass index, glucose tolerance, lipids, steroid myopathy, skin toxicity, neuropsychiatric toxicity, and infection. A higher GTI indicates greater glucocorticoid toxicity. The GTI contains the Cumulative Worsening Score (CWS) that captures cumulative toxicity over the course of time, and the Aggregate Improvement Score (AIS) that captures both improvement and worsening of toxicity over time.
The two GTI scores (CWS and AIS) of the avacopan group versus the comparator group are summarised in Table 6. The GTI measures were secondary endpoints in the study and not controlled for multiplicity.
\*\*Table 6: Glucocorticoid Toxicity Index results in the pivotal phase 3 ADVOCATE study (Intent-to-Treat Population)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*Avacopan\*\* \*\*N = 166\*\* | \*\*Comparator\*\* \*\*N = 164\*\* | \*\*Difference between Groups, 95% CI\*\* |
| \*\*Cumulative Worsening Score (CWS)\*\* | | | |
| Week 13 (least squares mean) | 25.7 | 36.6 | −11.0 (−19.7, −2.2) |
| Week 26 (least squares mean) | 39.7 | 56.6 | −16.8 (−25.6, −8.0) |
| \*\*Aggregate Improvement Score (AIS)\*\* | | | |
| Week 13 (least squares mean) | 9.9 | 23.2 | −13.3 (−22.2, −4.4) |
| Week 26 (least squares mean) | 11.2 | 23.4 | −12.1 (−21.1, −3.2) |
\*\*Paediatric population\*\*
A total of 3 adolescents were studied in the pivotal phase 3 ADVOCATE study, two in the avacopan group and one in the comparator group. One adolescent in the avacopan group discontinued treatment due to worsening renal vasculitis. The second adolescent patient who received avacopan completed treatment, achieved both remission at week 26 and sustained remission at week 52.
The adolescent in the comparator group discontinued treatment due to non-adherence to contraception.
The European Medicines Agency has deferred the obligation to submit the results of studies with avacopan in one or more subsets of the paediatric population in treatment of ANCA-associated vasculitis (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
When administered without food, avacopan peak plasma concentration (Cmax) occurs at a median time (tmax) of approximately 2 hours. Avacopan has shown an approximate dose-proportional increase in systemic exposure in the dose range of 10 to 30 mg.
Co-administration of 30 mg in capsule formulation with a high-fat, high-calorie meal increases the plasma exposure (AUC) of avacopan by approximately 72% and delays tmax by approximately 3 hours; however, the Cmax is not affected.
\*\*Distribution\*\*
The reversible plasma protein binding (e.g., to albumin and α1-acid glycoprotein) of avacopan and metabolite M1 is greater than 99.9%. The apparent volume of distribution is high (Vz/F 3,000 – 11,000 L), indicating broad tissue distribution of the active substance.
\*\*Biotransformation\*\*
Avacopan is eliminated mainly through phase I metabolism. Following oral administration of radiolabelled avacopan, the bulk of the active substance-related materials was recovered in faeces in the form of phase I metabolites. One major circulating metabolite (M1), a mono-hydroxylated product of avacopan, was present at ~ 12% of the total active substance-related materials in plasma. This metabolite constitutes 30 to 50% of the parent exposure and has approximately the same activity as avacopan on C5aR1. Cytochrome P450 (CYP) 3A4 is the major enzyme responsible for the clearance of avacopan and for the formation and clearance of metabolite M1.
Clinical interaction of avacopan with the sensitive CYP3A4 substrate simvastatin is described in section 4.5. Avacopan is a weak inhibitor of CYP2C9 as indicated by a modest increase in the AUC of the probe active substance celecoxib (1.15‑fold).
\*In vitro\*, avacopan is not an inhibitor of other CYP enzymes and is not an inducer of CYP enzymes.
Avacopan showed negligible to weak inhibition of common transporters \*in vitro\*. Therefore, clinically relevant interactions are unlikely when avacopan is co-administered with substances that are substrates or inhibitors of these transporters.
\*\*Elimination\*\*
Based on population pharmacokinetic analysis, the total apparent body clearance (CL/F) of avacopan is 16.3 L/h (95% CI: 13.1 – 21.1 L/h). The median terminal elimination half-life is 510 hours (21 days) based on population pharmacokinetic analysis. When avacopan is stopped after steady state has been reached, the residual plasma concentration of avacopan is projected to decrease to ~ 20%, < 10%, and < 5% of the steady state maximum concentration approximately 4 weeks, 7 weeks, and 10 weeks, respectively, after the last dose.
Following oral administration of radiolabelled avacopan, about 77% and 10% of the radioactivity was recovered in faeces and urine, respectively, and 7% and < 0.1% of the radioactive dose was recovered as unchanged avacopan in faeces and urine, respectively. These results suggest that the main route of clearance of avacopan is metabolism followed by biliary excretion of the metabolites into faeces, and that direct excretion of avacopan into urine or faeces via bile is negligible.
\*\*Special populations\*\*
\*Elderly\*
Population pharmacokinetic analysis found no significant effect of age (among adults) on the plasma exposure of avacopan; however, there were limited pharmacokinetic data in patients over 75 years of age in clinical studies. No dose adjustment is necessary for elderly patients (see section 4.2).
\*Hepatic impairment\*
The pharmacokinetic properties of avacopan have been examined in 16 patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment. When compared to normal controls, no pharmacologically relevant differences in exposure (mean ratios of Cmax and AUC ≤ 1.3) of avacopan or its major metabolite M1 was observed; therefore, no dose adjustment is necessary (see section 4.2).
Avacopan has not been studied in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.2).
\*Renal impairment\*
Based on population pharmacokinetic analysis, the plasma exposure of avacopan is similar between patients with renal impairment and healthy subjects. Therefore, no dose adjustment is necessary based on renal function (see section 4.2).
Avacopan has not been studied in patients with ANCA-associated vasculitis with an eGFR below 15 mL/min/1.73 m2, who are on dialysis, in need of dialysis or plasma exchange.5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenicity.
\*\*Fertility and early embryonic development\*\*
Avacopan produced no effects on male or female reproductive performance (fertility) or early development in hamsters at oral doses equivalent up to 6.8‑fold the clinical AUC.
Embryo-foetal development
Avacopan was not teratogenic when dosed orally to hamsters and rabbits. In hamsters, an increased incidence of skeletal variations (short thoracolumbar supernumerary rib) was observed at exposure equivalent to 5.3‑fold the clinical AUC. In rabbits, avacopan caused maternal toxicity (adverse clinical signs and abortions), but no foetal toxicity at 0.6‑fold the clinical AUC.
Pre- and post-natal development
Avacopan did not result in adverse effects in female offspring when administered in hamsters at exposures up to 6.3‑fold the clinical AUC during gestation and through lactation until weaning. In males, there was a slight delay in preputial separation at 3.7-fold the clinical AUC. This isolated finding was considered to be of low toxicological significance and was not associated with any impairment of reproductive performance.
Analysis of avacopan plasma levels in the lactating dams and the plasma levels in nursing offspring showed the presence of avacopan, suggesting that avacopan is likely secreted into the milk of lactating hamsters.
Carcinogenicity
The carcinogenic potential of avacopan was evaluated in a 2‑year study in both rats and hamsters.
In male rats, a slightly increased incidence of C‑cell thyroid adenoma was noted in avacopan-treated rats; this increase was not statistically significant, and the incidence was within the historical control range. Avacopan was not carcinogenic in hamsters, the pharmacologically relevant species.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Capsule content\*\*
Macrogolglycerol hydroxystearate
Macrogol (4000)
\*\*Capsule shell\*\*
Gelatin
Red iron oxide (E172)
Yellow iron oxide (E172)
Titanium dioxide (E171)
Polysorbate 80
\*\*Imprinting ink\*\*
Black iron oxide (E172)
Shellac
Potassium hydroxide6.2 Incompatibilities
Not applicable.6.3 Shelf life
4 years6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions.
Store in the original bottle in order to protect from light.6.5 Nature and contents of container
High density polyethylene (HDPE) bottle with child-resistant closure and induction seal.
Pack sizes of 30 or 180 hard capsules.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
